Aspen Neuroscience, Inc.
Aspen Neuroscience, a clinical-stage regenerative medicine company, filed an S-1 for an IPO on Nasdaq under the symbol "ASPE." The company's lead candidate, sasineprocel, is an autologous iPSC-derived cell therapy for Parkinson's disease currently in a Phase 1/2a ASPIRO trial. As of the August 18, 2026 data cutoff, 15 patients had been dosed, with sustained motor and quality-of-life improvements observed. The offering is underwritten by Leerink Partners, UBS, Piper Sandler, Stifel, and Oppenheimer. Pricing terms and share count remain blank in the preliminary prospectus.
- Lead candidate sasineprocel is an autologous iPSC-derived cell therapy for Parkinson's disease, currently in a Phase 1/2a ASPIRO trial with
- As of August 18, 2026, 15 patients had been dosed; improvements in Good On Time and MDS-UPDRS Part III OFF exceeded clinically meaningful
- Sasineprocel has received FDA RMAT designation for levodopa-responsive PD and Fast Track designation for PD to improve motor function.
- The autologous approach requires no immunosuppression post-administration, a key differentiator from allogeneic competitors.
- Phase 3 biopsy collection expected by end of 2026; Phase 3 dosing anticipated in the second half of 2027.
Price data unavailable.
First autologous iPSC-derived Parkinson's therapy to reach IPO stage with clinical data showing no immunosuppression requirement and sustained efficacy signals — a potential paradigm shift in CNS cell
Aspen enters a competitive CNS cell therapy landscape alongside allogeneic Parkinson's programs from BlueRock Therapeutics (Bayer) and others. The autologous, no-immunosuppression approach is a key differentiator, though manufacturing complexity and cost per patient remain open questions for the aut
The ASPIRO trial is open-label with no placebo or control cohort, limiting interpretability of efficacy data. The clinically meaningful change benchmarks have not been discussed with the FDA or independently validated. No assurance RMAT or Fast Track designation accelerates approval.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.